+514.3%
MRNA vs CHTR
-45.8%
+560.1%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | CHTR | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.9% | -1.7% | +3.5% | +2.4% |
| 7D | +0.8% | -5.7% | +6.5% | +2.4% |
| 30D | +131.7% | -7.1% | +138.7% | +135.6% |
| 3M | +193.9% | -1.7% | +195.6% | +195.8% |
| 6M | +179.1% | -34.3% | +213.4% | +195.8% |
| YTD | +397.4% | -31.3% | +428.8% | +424.6% |
| All | +514.3% | -45.8% | +560.1% | +524.1% |
Cumulative growth
Daily Returns
Daily percentage return beside CHTR.
Daily Out/Under-Performance
Portfolio return minus CHTR return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × CHTR return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded CHTR wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling